GlassScriptPhysician profile
Vian Murad
NPI 1053961482
$1,581.60
in general payments reported to CMS, 2019-2025
23 companies · $587 in 2025
The $587 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $236 · 2023: $259 · 2024: $378 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,223.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $240.62 | 2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $172.11 | 2024-2025 | Entyvio, Hyqvia |
| E.R. Squibb & Sons, L.L.C. | $150.54 | 2021-2023 | Orencia |
| Tg Therapeutics, INC. | $149.94 | 2025 | |
| Lundbeck LLC | $118.79 | 2022-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $98.97 | 2022-2024 | |
| Amgen INC. | $93.57 | 2022-2025 | Evenity, Prolia, Krystexxa |
| Alexion Pharmaceuticals, INC. | $83.54 | 2022-2025 | Ultomiris |
| Horizon Therapeutics Plc | $82.61 | 2022-2023 | Krystexxa, Uplizna |
| Lilly USA, LLC | $59.32 | 2024-2025 | Omvoh, Kisunla |
| Janssen Biotech, INC. | $46.40 | 2024 | Stelara |
| Genentech USA, INC. | $44.54 | 2022 | |
| Pharmacosmos Therapeutics INC. | $31.25 | 2024 | Monoferric |
| Astrazeneca Pharmaceuticals LP | $27.62 | 2023 | |
| Fresenius Kabi USA, LLC | $27.49 | 2024 | Idacio |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $23.72 | 2023 | Qutenza |
| Glaxosmithkline, LLC. | $23.69 | 2024 | Jemperli |
| Regeneron Healthcare Solutions, INC. | $23.19 | 2023 | Libtayo |
| Abbvie INC. | $21.21 | 2024 | |
| Eisai INC. | $20.46 | 2023 | |
| Daiichi Sankyo INC. | $17.06 | 2022 | |
| Merck Sharp & Dohme LLC | $14.44 | 2022 | |
| Organon LLC | $10.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vian Murad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.